BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:safusidenib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of safusidenib\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05303519-10904@assetmemo.bio
DTSTAMP:20261121T005934Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:safusidenib: Phase 3 readout est. (NCT05303519)
DESCRIPTION:safusidenib\, phase 3\, Glioma.\nStudy: SIGMA (Safusidenib in I
 DH1 Mutant Glioma Maintenance)\nEstimated primary completion: 1 December 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/safusidenib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05303519
URL:https://assetmemo.bio/drug/safusidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07832123-10904@assetmemo.bio
DTSTAMP:20261121T005934Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:safusidenib: Phase 2 readout est. (NCT07832123)
DESCRIPTION:safusidenib\, phase 2\, Glioma.\nStudy: Safusidenib for Patient
 s With Newly Diagnosed IDH1-mutant CNS WHO Grade 3 Oligodendroglioma and A
 strocytoma - a Single Arm Phase II Study\nEstimated primary completion: Ma
 rch 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/safusidenib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078
 32123
URL:https://assetmemo.bio/drug/safusidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07712757-10904@assetmemo.bio
DTSTAMP:20261121T005934Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:safusidenib: Phase 3 readout est. (NCT07712757)
DESCRIPTION:safusidenib\, phase 3\, Glioma.\nStudy: Safety and Efficacy Stu
 dy of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma\nEstimat
 ed primary completion: May 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/safusidenib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07712757
URL:https://assetmemo.bio/drug/safusidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07703436-10904@assetmemo.bio
DTSTAMP:20261121T005934Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:safusidenib: Phase 2 readout est. (NCT07703436)
DESCRIPTION:safusidenib\, phase 2\, Glioma.\nStudy: Safety and Efficacy Stu
 dy of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued
  Vorasidenib Treatment Due to Progressive Disease\nEstimated primary compl
 etion: September 2030. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/safusidenib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07703436
URL:https://assetmemo.bio/drug/safusidenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
